AU2016240020B2 - Antibody that recognises the T14 peptide of AChE - Google Patents

Antibody that recognises the T14 peptide of AChE Download PDF

Info

Publication number
AU2016240020B2
AU2016240020B2 AU2016240020A AU2016240020A AU2016240020B2 AU 2016240020 B2 AU2016240020 B2 AU 2016240020B2 AU 2016240020 A AU2016240020 A AU 2016240020A AU 2016240020 A AU2016240020 A AU 2016240020A AU 2016240020 B2 AU2016240020 B2 AU 2016240020B2
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016240020A
Other languages
English (en)
Other versions
AU2016240020A1 (en
Inventor
Sara GARCIA-RATES
Susan Greenfield
Paul MORRILL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuro Bio Ltd
Original Assignee
Neuro Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Bio Ltd filed Critical Neuro Bio Ltd
Publication of AU2016240020A1 publication Critical patent/AU2016240020A1/en
Application granted granted Critical
Publication of AU2016240020B2 publication Critical patent/AU2016240020B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AU2016240020A 2015-03-27 2016-03-23 Antibody that recognises the T14 peptide of AChE Ceased AU2016240020B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1505239.2 2015-03-27
GB1600871.6 2016-01-18
GB1600871.6A GB2541477A (en) 2015-03-27 2016-01-18 Antibody
PCT/GB2016/050804 WO2016156803A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache

Publications (2)

Publication Number Publication Date
AU2016240020A1 AU2016240020A1 (en) 2017-11-02
AU2016240020B2 true AU2016240020B2 (en) 2022-02-17

Family

ID=53178191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016240020A Ceased AU2016240020B2 (en) 2015-03-27 2016-03-23 Antibody that recognises the T14 peptide of AChE

Country Status (13)

Country Link
US (1) US10954306B2 (enExample)
EP (1) EP3274371B1 (enExample)
JP (1) JP7327897B2 (enExample)
KR (1) KR102626626B1 (enExample)
CN (1) CN107531796A (enExample)
AU (1) AU2016240020B2 (enExample)
BR (1) BR112017020769A2 (enExample)
CA (1) CA2979972A1 (enExample)
ES (1) ES2952723T3 (enExample)
GB (2) GB201505239D0 (enExample)
MX (1) MX392158B (enExample)
RU (1) RU2729491C2 (enExample)
WO (1) WO2016156803A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
GB202112831D0 (en) * 2021-09-09 2021-10-27 Neuro Bio Ltd Biomarker
GB202113941D0 (en) 2021-09-29 2021-11-10 Neuro Bio Ltd Skin biomarker
EP4584388A1 (en) 2022-09-08 2025-07-16 Neuro-Bio Ltd Lateral flow device for diagnosing alzheimer's disease using the t14 peptide
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease
GB202308779D0 (en) * 2023-06-13 2023-07-26 Neuro Bio Ltd Aptamer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035962A1 (en) * 1996-03-22 1997-10-02 Synaptica Limited Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038875A1 (en) 2000-03-29 2004-02-26 Greenfield Susan Adele Alpha 7nicotinic receptor screening assays
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
BRPI0615997A8 (pt) * 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
GB0708646D0 (en) * 2007-05-04 2007-06-13 Enkephala Ltd Biologically active C-terminal fragment of acetylcholinesterase
WO2009040789A2 (en) * 2007-09-24 2009-04-02 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN101530162B (zh) * 2008-03-10 2011-11-23 北京大北农科技集团股份有限公司 一种新型蛋白饲料添加剂的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035962A1 (en) * 1996-03-22 1997-10-02 Synaptica Limited Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator

Also Published As

Publication number Publication date
US20180051094A1 (en) 2018-02-22
US10954306B2 (en) 2021-03-23
WO2016156803A1 (en) 2016-10-06
RU2017133649A3 (enExample) 2020-02-17
GB2541477A (en) 2017-02-22
JP7327897B2 (ja) 2023-08-16
RU2017133649A (ru) 2019-04-29
MX392158B (es) 2025-03-21
CA2979972A1 (en) 2016-10-06
AU2016240020A1 (en) 2017-11-02
GB201505239D0 (en) 2015-05-13
KR20170138414A (ko) 2017-12-15
JP2018516849A (ja) 2018-06-28
RU2729491C2 (ru) 2020-08-07
MX2017012397A (es) 2018-01-26
ES2952723T3 (es) 2023-11-03
EP3274371B1 (en) 2023-06-07
CN107531796A (zh) 2018-01-02
KR102626626B1 (ko) 2024-01-17
GB201600871D0 (en) 2016-03-02
EP3274371A1 (en) 2018-01-31
BR112017020769A2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
US10954306B2 (en) Antibody that recognises the T14 peptide of AChE
US11739140B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10647762B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
KR102786111B1 (ko) 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
TW201716440A (zh) 用於治療共核蛋白病的藥劑、用途及方法
EP3565836A1 (en) Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
AU2017211526B2 (en) Cancer
CA2990555C (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ ANTIBODY THAT RECOGNISES THE T14 PEPTIDE OF ACHE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired